Medicago “first in the world” to report positive pre-clinical data for H7N9 vaccine

Medicago has announced that it is "first in the world" to report positive interim results from a pre-clinical trial for an H7N9 Virus-Like Particle (VLP) vaccine candidate. The company reports that three micrograms of its H7 vaccine administered with and without adjuvant induced high antibody titres after one dose. According to Andy Sheldon, President and CEO of Medicago, the results …